ArticleJAC-antimicrobial resistance2026
Impact of third-generation cephalosporin and carbapenem resistance profiles on the mortality of patients with
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate 30-day mortality in Methods: Multicentre retrospective cohort including adults with healthcare-associated Ecc BSI from four Brazilian tertiary hospitals. Isolates were categorized as: third-generation cephalosporin-susceptible (3GCS), third-generation cephalosporin-resistant (3GCR), or carbapenem-resistant (CR). A hierarchical Cox model assessed the effect of resistance profiles on 30-day mortality, adjusting sequentially for: (i) baseline status, (ii) BSI-related variables and (iii) antimicrobial therapy. Results: Of 429 patients, 300 (69.9%) had 3GCS, 103 (24.0%) 3GCR and 26 (6.1%) CR Ecc BSIs. Thirty-day mortality was 22.6% (20.6%, 25.2% and 34.6%, respectively; Conclusions: Non-statistically significant mortality rates were observed in patients with 3GCR and CR Ecc BSIs. Baseline severity and, most importantly, less frequent appropriate antimicrobial therapy attenuated the effect of resistance profiles on the outcome. Improving antimicrobial therapy against resistant Ecc isolates has great potential to reduce mortality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.